You are here
Home > Renal > Cefotetan

Usual Dosing (Adults)

Usual: 1-2 grams q12h. 
[Life-threatening]: 3 grams IV q12h.

General Guidelines for Dosage of CEFOTAN

Type of Infection Daily Dose Frequency and Route
Klebsiella pneumoniae skin and skin structure infections should be treated with 1 or 2 grams every 12 hours IV or IM.
Maximum daily dosage should not exceed 6 grams.
Urinary Tract 1-4 grams 500 mg every 12 hours IV or IM
1 or 2 g every 24 hours IV or IM 1 or
2 g every 12 hours IV or IM
Skin & Skin Structure Mild - Moderate 2 grams 2 g every 24 hours IV
1 g every 12 hours IV or IM
Severe 4 grams 2 g every 12 hours IV
Other Sites 2 - 4 grams 1 or 2 g every 12 hours IV or IM
Severe 4 grams 2 g every 12 hours IV
Life-Threatening 6 grams 3 g every 12 hours IV

If Chlamydia trachomatis is a suspected pathogen in gynecologic infections, appropriate antichlamydial coverage should be added, since cefotetan has no activity against this organism.

To prevent postoperative infection in clean contaminated or potentially contaminated surgery in adults, the recommended dosage is 1 or 2 g of CEFOTAN administered once, intravenously, 30 to 60 minutes prior to surgery. In patients undergoing cesarean section, the dose should be administered as soon as the umbilical cord is clamped.

Renal Dosing

dialysis [CRCL >30 ml/min]: No changes

[10-30 ]: 1-2g q24h or 500mg-1g q12h

[<10 ml/min]: 1-2 grams q48h or 250-500mg q12h


dialysis Hemodialysis: 
250 - 500 mg q24h on non-HD days and 500 mg - 1 gm q24h on HD days
PD: 1 gram q24h


National Institutes of Health, U.S. National Library of Medicine, DailyMed Database.
Provides access to the latest drug monographs submitted to the Food and Drug Administration (FDA). Please review the latest applicable package insert for additional information and possible updates.  A local search option of this data can be found here.


The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user’s use of or reliance upon this material.PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. Read the disclaimer